EMA fast-tracks review of a medicine for metastatic pancreatic cancer

EMA begins phased review of daraxonrasib for metastatic pancreatic cancer treatment

Phased review has started to accelerate assessment of medicine with potential to address high unmet medical need

<![CDATA[EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process]]>

Daraxonrasib nearly doubles survival in advanced pancreatic cancer by targeting previously 'undruggable' mechanism

Around 97% of patients with advanced pancreatic cancer die within five years. Researchers have figured out a way to target the mechanism tha

First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know

Jun 1, 2026 - By Erin Post NEW — Additional Data on Daraxonrasib Released: “Significant Advances” for Pancreatic Cancer Treatment Daraxonras

Experimental Drug Daraxonrasib Shows First Major Survival Benefit for Pancreatic Cancer Patients

The new strategy also holds promise for lung and colon tumors. Here’s how scientists discovered it.

Daraxonrasib drug nearly doubles survival in advanced pancreatic cancer, oncologist reports

Breakthrough drug nearly doubles survival with advanced pancreatic cancer – an oncologist explains how daraxonrasib overcame an ‘undruggable